The neoadjuvant combination of avelumab (Bavencio) and axitinib (Inlyta) resulted in a partial response (PR) rate of 30% in patients with localized renal-cell carcinoma (RCC) at high risk for relapse after nephrectomy, according to results from the phase 2 NeoAvAx clinical trial.
Adjuvant pembrolizumab (Keytruda) continued to provide a disease-free survival (DFS) benefit in patients with renal-cell carcinoma (RCC) at intermediate-high or high risk of recurrence after nephrectomy, according to 30-month follow-up data from the KEYNOTE-564 trial presented at the 2022 ASCO Genitourinary Cancers Symposium.
In a keynote address during the virtual 2020 International Kidney Cancer Symposium, William G. Kaelin Jr, MD, Sidney Farber Professor of Medicine, Dana-Farber Cancer Institute, Boston, MA, provided an update on treatment strategies aimed at improving outcomes for patients with clear-cell renal-cell carcinoma (RCC) caused by inactivation of the VHL gene.
There has been an increased focus on the study of tumor alterations that may predict treatment benefit or serve as possible actionable targets in cancer. During the virtual American Urological Association 2020 Annual Meeting, Kyrollis Attalla, MD, Urology Oncology Fellow, Memorial Sloan Kettering Cancer Center, Ridgewood, NY, discussed findings of a recent study that looked at the landscape of actionable genomic alterations and the corresponding evidence to support these alterations as predictive of response to targeted therapy in patients with renal-cell carcinoma (RCC).
First-line therapy with pembrolizumab (Keytruda) plus axitinib (Inlyta) significantly improved overall survival (OS), progression-free survival (PFS), and objective response rates compared with standard-of-care sunitinib (Sutent) in patients with clear-cell metastatic renal-cell carcinoma (RCC) in KEYNOTE-426.
Combining an immune checkpoint inhibitor and a tyrosine kinase inhibitor (TKI) significantly improved progression-free survival (PFS) in treatment-naïve patients with advanced renal-cell carcinoma (RCC) compared with a TKI alone.
Progression-free survival (PFS) was extended by 3.5 months with first-line atezolizumab (Tecentriq) plus bevacizumab (Avastin) in patients with metastatic renal-cell carcinoma (RCC) versus standard-of-care sunitinib (Sutent) in the phase 3 IMmotion151 clinical trial presented at the 2018 Genitourinary Cancers Symposium